Share Twitter LinkedIn Facebook Email Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber offers his impression of the landscape for FLT3 inhibition in acute myeloid leukemia (AML).
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
Inequities in AML Outcomes: Comprehensive Discussion by Pramilla Krishnamurthy Acute Myelogenous Leukemia 2 Mins Read